Absci prices $100M common stock offering at $7.41/share; Lilly, other investors participate

Absci Corp

13,495,277 shares priced at $7.41 each; gross proceeds ~$100M, net ~$93.5M after fees.
Offering includes participation from Eli Lilly, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile.
Net proceeds to fund AI-designed anti-PRLR antibody ABS-201 for alopecia and endometriosis.
Offering expected to close June 25, 2026; Jefferies, J.P. Morgan, TD Cowen, Guggenheim as bookrunners.
Shares sold under effective shelf registration statement (File No. 333-289541).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.